Progresses in the pharmacological treatment of pulmonary arterial hypertension;Progresos en el tratamiento farmacológico de la hipertensión arterial pulmonar

Medicina Interna de Mexico

Volumn 20, Issue 3, 2004, Pages 208-220

  Aguilar, Mateo Porres ^a,c   Muñoz, Mateo Porres ^b  

^a UNIVERSIDAD LA SALLE   (Mexico)

^b Servicio de Medicina Interna   (Mexico)

^c NONE   (Mexico)

Author keywords

Pharmacological treatment; Pulmonary arterial hypertension

Indexed keywords

BOSENTAN; DILTIAZEM; ILOPROST; NIFEDIPINE; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; PULMONARY HYPERTENSION; REVIEW;

EID: 35348906690     PISSN: 01864866     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Porres AM, Ixcamparij RC, Porres MM, Mateo de Acosta DA. Hipertensión pulmonar primaria. Rev Esp Med-Quir ISSSTE 2002;7:14-22.
2. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "work in progress". Circulation 2000;102:2781-91.
3. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
4. Pulido T. ¿Qué es lo nuevo en el tratamiento de la hipertensión arterial pulmonar? Arch Cardiol Mex 2003;73:S121-4.
5. British Thoracic Society Guidelines and Medical Practice Committee. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86:S1-13.
6. Chatterjee K, De Marco T, Alpert JS. Pulmonary hypertension: hemodynamic diagnosis and management. Arch Intern Med 2002;162:1925-33.
7. Olschewski H, Rose F, Grunig E, Ghofrani A, et al. Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med 2001;138:367-77.
8. Fisherman AP, McGoon MD, Chazova IE, et al. Diagnosis and assessment of pulmonary hypertension. In: Primary pulmonary hypertension: executive summary of the World Symposium on primary pulmonary hypertension. Rich S, editor. Geneva: World Health Organization, 1998.
9. Giaid A. Nitric oxide and endothelin-1 in pulmonary arterial hypertension. Chest 1998;114:S208-12.
10. Giaid A, Saleh D. Reduced expression of the endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
11. Tuder RM, Cool CD, Gearci MW, Wang J, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary arterial hypertension. Am J Respir Crit Care Med 1999;159:1925-32.
12. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, et al. Expression of endothelin-1 in the lungs of patients with pulmonary arterial hypertension. N Engl J Med 1993;328:1732-9.
13. Newman JH, Wheeler L, Lane KB, Loyd E, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319-24.
14. Deng Z, Morse JH, Slager S, Cuervo N, et al. Familial primary pulmonary hypertension (gene PPH-1) is caused by mutations in the bone morphogenetic protein receptor II gene. Am J Hum Genet 2000;67:737-44.
15. Tuder RM, Yeager ME, Geraci MW, Golpon HA, et al. Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene. Eur Respir J 2001;17:1065-9.
16. Morrell NW, Yang X, Upton PD, Jourdan KB, et al. Altered growth response of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor beta-1 and bone morphogenetic proteins. Circulation 2001;104:790-5.
17. Yeager M, Halley GR, Golpon HA, Voelkel NF, et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in pulmonary arterial hypertension. Circ Res 2001;88:E2-11.
18. Yuan JX, Aldinger AM, Juhaszova M, Wang J, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with pulmonary arterial hypertension. Circulation 1998;98:1400-6.
19. Rabinovitch M. Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension. J Clin Invest 2001;108:1109-11.
20. Gildea TR, Arroliga AC, Minai OA. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension. Clev Clin J Med 2003;70:S18-27.
21. Robbins IM, Christman BW, Newman JH, et al. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998;114:1269-75.
22. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
23. Rich S, Brundage BH. High dose calcium channel blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
24. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996;334:296-301.
25. McLaughlin VV, Meyer PM, Rich S. Optimal dosage range of prostacyclin for patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2000;161:A458.
26. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
27. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
28. Simmoneau G, Barst RJ, Galie N, Naejie R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double blind randomized controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
29. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med 2000;132:435-43.
30. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolised iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000;35:176-82.
31. Olschewski H, Simonneau G, Galie N, Higenbottam T, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
32. Nagaya N, Uematsu M, Okano Y, Kyotani S, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1188-92.
33. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502.
34. Barst RJ, McGoon M, McLaughlin V, Tapson V, Oudiz R, Shapiro S, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25.
35. Levin ER. Endothelins. In: Epstein FH, editor. Mechanisms of disease. N Engl J Med 1995;333:356-62.
36. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003;108:2184-90.
37. Yang Z, Krasniei N, Luschner TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ET-A and ET-B receptor blockade. Circulation 1999;100:5-8.
38. Tuder RM, Cool CD, Yeager M, Taraseviciene SL, Bull TM, et al. The pathophysiology of pulmonary hypertension: the endothelium. Clin Chest Med 2001;22:405-18.
39. Cheng JWM. Drug highlight: Bosentan. Heart Dis 2003;5:161-9.
40. Channick RN, Simonneau G, Sitbon O, Robbins I, Frost A, Tapson VF, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23.
41. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
42. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1 year follow up study. Chest 2003;124:247-54.
43. Humbert M, Barst RJ, Robbins IM, et al. Safety and efficacy of bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:A441.
44. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an oral endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest 2002;121:1860-8.
45. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan, a selective ET-a antagonist improves cardiopulmonary hemodynamics in pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:A273.
46. Dweik RA. Pulmonary hypertension and the search for the selective pulmonary vasodilator (commentary). Lancet 2002;360:286-7.
47. Cheitlin MD, Hutter AM, Brindis RG, Ganz P, Kaul S, et al. Use of sildenafil (viagra) in patients with cardiovascular disease. Circulation 1999;99:168-77.
48. Wilkens H, Guth A, Koenig J, Forestier N, Cremers B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22.
49. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-403.
50. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-22.
51. Michelakis ED, Tymchak W, Noga M, Webster L, Chen Wu X, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9.